|Page (1) of 1 - 08/04/17||email article||print page|
(August 04, 2017)
MISSION VIEJO, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) -- MYnd Analytics, Inc. (NASDAQ:MYND), a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error treatment in mental health, announced the addition of Leila Colgan, as Vice President of Sales and Marketing, an experienced diagnostic/pharma executive to its ranks.
Ms. Colgan is an accomplished, results-oriented professional with over 20 years of leadership experience in sales and marketing within the pharmaceutical, biotech and oncology/genomic diagnostic space including organizations such as Clarient, a GE Healthcare Co, (acquired by NeoGenomics in 2015) Amgen, Inc., AstraZeneca, Pfizer (Agouron), Merck & Co. Inc. and Abbott Laboratories. Her depth of industry knowledge and her proven ability to build high-performance teams will be a key in leading the Companys revenue growth.
Ms. Colgan has consistently exceeded corporate and market share growth targets, and is a recipient of multiple national and local achievement awards throughout her career. She is a visionary executive known for championing business growth and innovation through sales leadership, marketing, business development, and operational oversight while elevating organizations into top revenue-generating entities. An insightful leader with a reputation for forging profitable partner/customer relationships, and aligning sales/promotion functions to maximize revenue and return on investment (ROI), Ms. Colgan received her Bachelors of Arts and her Executive MBA from Pepperdine University, graduating with Beta Gamma Sigma Honors.
George Carpenter, MYnds CEO, said ?Leilas market expertise, industry connections, sales acumen, and ability to build key relationships will be key to our success, and is a fantastic addition to our growing world class executive team.
Ms. Colgan stated ?I am thrilled to have the opportunity to lead the sales and marketing efforts at MYnd Analytics as we provide better tools for mental health professionals to help decrease trial and error prescribing for their patients.
About MYnd Analytics, Inc.
MYnd Analytics, Inc. (www.myndanalytics.com) is a predictive medicine company which brings objective physical findings to psychiatric treatment in order to reduce trial and error prescribing. The Companys Psychiatric EEG Evaluation Registry, or PEER Online®, is a registry and reporting platform that allows medical professionals to exchange treatment outcome data for patients referenced to objective neurophysiology data obtained through a standard electroencephalogram (EEG). Based on the Companys original physician developed database, there are now more than 38,000 outcomes for over 10,000 unique patients in the PEER registry. The goal of PEER Online® is to provide objective, personalized data to assist physicians in the selection of appropriate medications.
To read more about the benefits of this patented technology for patients, physicians and payers, please visit www.myndanalytics.com.
CONTACT: Contact:Stan WunderlichInvestor Relations,CFSG1800firstname.lastname@example.org
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter